里瓦斯蒂格明 - 班布醇杂交物作为选择性丁胆酶抑制剂
Jie Wu1, Zekai Tan2, Marco Pistolozzi3
1School of Food & Pharmaceutical Engineering, Zhaoqing University, Zhaoqing 526061, China.
研究人员开发了用于阿尔茨海默病治疗的新型布基胆酶抑制剂. 化合物MTR-3显示出高强度和选择性,显示出未来药物发现的前景.
科学领域:
- 神经科学是一个神经科学.
- 药用化学 医学化学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病.
- 选择性butirycholinesterase (BChE) 抑制剂是阿尔茨海默病的一个有前途的治疗策略.
研究的目的:
- 为了合成和评估新型的里瓦斯蒂格胺 - 班布醇混合物作为潜在的BCHE抑制剂.
- 为了识别具有高BChE选择性和AD治疗抑制潜力的化合物.
主要方法:
- 合成,净化和表征一种里瓦斯蒂格胺 - 班布醇混合物和14种类似物.
- 在体外胆化酶测试以确定对BCHE和乙胆化酶 (AChE) 的抑制活性.
主要成果:
- 所有合成的化合物对BChE的疗效都比AChE更强.
- 化合物MTR-3显示出优异的BCHE抑制 (IC50 = 78nM) 具有高的选择性 (IC50>100,000nM对ACHE).
- 与 bambuterol相比,MTR-3 显示出穿透血脑屏障和长时间抑制 BChE 的潜力.
结论:
- 新型混合化合物是强效和选择性的BCHE抑制剂.
- MTR-3 是一种用于开发针对阿尔茨海默病的特定BChE抑制剂的化合物.
- 这项研究为发现有效的阿尔茨海默病治疗方法提供了新的途径.
更多相关视频
09:39Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
Published on: January 27, 2014
08:21Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
Published on: June 28, 2019
相关概念视频
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Direct-Acting Cholinergic Agonists: Therapeutic Uses
